Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Yousif Capital Management LLC

Yousif Capital Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 334,083 shares of the company’s stock after selling 13,237 shares during the quarter. Johnson & Johnson accounts for about 0.5% of Yousif Capital Management LLC’s investment portfolio, making the stock its 21st largest holding. Yousif Capital Management LLC’s holdings in Johnson & Johnson were worth $48,315,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Cassia Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 59.5% during the fourth quarter. Cassia Capital Partners LLC now owns 5,538 shares of the company’s stock worth $801,000 after purchasing an additional 2,065 shares during the period. Avitas Wealth Management LLC lifted its position in Johnson & Johnson by 0.6% in the 4th quarter. Avitas Wealth Management LLC now owns 30,181 shares of the company’s stock worth $4,365,000 after buying an additional 182 shares in the last quarter. Redwood Wealth Management Group LLC grew its holdings in shares of Johnson & Johnson by 3.2% during the 4th quarter. Redwood Wealth Management Group LLC now owns 4,020 shares of the company’s stock valued at $580,000 after acquiring an additional 124 shares in the last quarter. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $32,000. Finally, E. Ohman J or Asset Management AB raised its holdings in shares of Johnson & Johnson by 12.1% during the fourth quarter. E. Ohman J or Asset Management AB now owns 109,740 shares of the company’s stock worth $15,871,000 after acquiring an additional 11,840 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Citigroup decreased their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Bank of America reduced their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Finally, Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $153.10 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a fifty day moving average price of $147.46 and a 200 day moving average price of $156.06. The stock has a market cap of $368.61 billion, a P/E ratio of 23.02, a PEG ratio of 2.44 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the company earned $2.29 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s payout ratio is 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.